Literature DB >> 7672685

A controlled study of bone mineral density in patients with inflammatory bowel disease.

J A Silvennoinen1, T J Karttunen, S E Niemelä, J J Manelius, J K Lehtola.   

Abstract

To assess the prevalence of and risk factors for low bone mineral density in inflammatory bowel disease (IBD), 152 IBD patients and 73 healthy controls were studied. Sixty seven patients had ulcerative colitis, 78 had Crohn's disease (52 of them (66.7%) had ileal disease), and seven had indeterminate colitis. Bone mineral density values (g/cm2) measured by dual energy x ray absorbtiometry at the spine (L2-L4), the femoral neck, Ward's triangle, and the trochanter were 1.177, 0.948, 0.850, and 0.838 in the patients and 1.228 (p = 0.034), 1.001 (p = 0.009), 0.889 (NS), and 0.888 (p = 0.012) in the control group, respectively. The type or extent of the disease or previous small bowel resection did not have any significant effect on the bone mineral density values. There was a weak, but statistically significant negative correlation between bone mineral density and the total lifetime corticosteroid dose (in the lumbar spine r = -0.164, p = 0.04, the femoral neck r = -0.185, p = 0.02, Ward's triangle r = -0.167, p = 0.04, and the trochanter r = -0.237, p = 0.003). The patients whose lifetime corticosteroid dose (prednisone/prednisolone) was more than 10 g had especially low bone mineral density (p < 0.05 compared with the groups with no or less than 5 g of corticosteroid). The patients who had never taken peroral corticosteroids did not have decreased bone mineral density. In conclusion, IBD patients have significantly lower bone mineral density values than healthy controls, but the difference is not so great as has been reported previously. Low bone mineral density values in these patients are related to high lifetime corticosteroid doses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672685      PMCID: PMC1382771          DOI: 10.1136/gut.37.1.71

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Bone mineral density measured by dual-energy X-ray absorptiometry in normal men.

Authors:  H Kröger; K Laitinen
Journal:  Eur J Clin Invest       Date:  1992-07       Impact factor: 4.686

2.  Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers.

Authors:  H Kröger; J Heikkinen; K Laitinen; A Kotaniemi
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

Review 3.  Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA).

Authors:  R B Mazess; H S Barden
Journal:  Ann Chir Gynaecol       Date:  1988

4.  Crohn's disease. History and case report of associated metatarsal stress fracture.

Authors:  J J Bartley
Journal:  J Am Podiatr Med Assoc       Date:  1989-02

5.  Osteoporosis after long-term corticosteroid treatment of giant cell arteritis.

Authors:  R Andersson; A Rundgren; K Rosengren; B A Bengtsson; B E Malmvall; D Mellström
Journal:  J Intern Med       Date:  1990-06       Impact factor: 8.989

6.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

7.  The incidence of Crohn's disease is not decreasing in Sweden.

Authors:  E Lindberg; G Jörnerot
Journal:  Scand J Gastroenterol       Date:  1991-05       Impact factor: 2.423

8.  Baseline measurement of bone mass predicts fracture in white women.

Authors:  S L Hui; C W Slemenda; C C Johnston
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

9.  Bone disease in vitamin D-deficient patients with Crohn's disease.

Authors:  H Vogelsang; P Ferenci; W Woloszczuk; H Resch; C Herold; S Frotz; A Gangl
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

10.  Low bone mineral density in patients with inflammatory bowel disease.

Authors:  F Pigot; C Roux; S Chaussade; D Hardelin; O Pelleter; T Du Puy Montbrun; V Listrat; M Dougados; D Couturier; B Amor
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

View more
  40 in total

1.  Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology.

Authors:  E M Scott; I Gaywood; B B Scott
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 3.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

4.  Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.

Authors:  J Jahnsen; J A Falch; E Aadland; P Mowinckel
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

5.  Longitudinal study of bone mineral density in patients with Crohn's disease.

Authors:  D J de Jong; L Mannaerts; L G M van Rossum; F H M Corstens; A H J Naber
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

6.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

7.  Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.

Authors:  Gaurav Arora; Gurkirpal Singh; Shweta Vadhavkar; Shamita B Shah; Ajitha Mannalithara; Alka Mithal; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

8.  Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases.

Authors:  A Nemetz; M Tóth; M A García-González; T Zágoni; J Fehér; A S Peña; Z Tulassay
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.

Authors:  A R Moschen; A Kaser; B Enrich; O Ludwiczek; M Gabriel; P Obrist; A M Wolf; H Tilg
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

10.  Osteoporosis and determinants of bone density in patients with Crohn's disease.

Authors:  R J Robinson; F al-Azzawi; S J Iqbal; T Kryswcki; L Almond; K Abrams; J F Mayberry
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.